Technology - Technology Distributors - NASDAQ - US
$ 53.07
0.0566 %
$ 4.61 B
Market Cap
13.82
P/E
Avnet, Inc., a technology solutions company, markets, sells, and distributes electronic components. The company operates through two segments, Electronic Components and Farnell. The Electronic Components segment markets, sells, and distributes semiconductors; interconnect, passive, and electromechanical devices; and other integrated components from electronic component manufacturers. It also offers design chain support that provides engineers with technical design solutions; engineering and technical resources to support product design, bill of materials development, and technical education and training; and supply chain solutions that provide support and logistical services to original equipment manufacturers, electronic manufacturing service providers, and electronic component manufacturers. In addition, this segment provides integrated solutions, such as technical design, integration, and assembly of embedded products, and systems and solutions primarily for industrial applications, as well as for intelligent and innovative embedded display solutions comprising touch and passive displays.[ Read More ]
The intrinsic value of one AVT stock under the base case scenario is HIDDEN Compared to the current market price of 53.1 USD, Avnet, Inc. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart AVT
FINANCIALS
23.8 B
REVENUE
897 M
OPERATING INCOME
499 M
NET INCOME
690 M
OPERATING CASH FLOW
-225 M
INVESTING CASH FLOW
-434 M
FINANCING CASH FLOW
5.6 B
REVENUE
142 M
OPERATING INCOME
59 M
NET INCOME
106 M
OPERATING CASH FLOW
-31.4 M
INVESTING CASH FLOW
-109 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Avnet, Inc.
| Current Assets | 10.4 B |
| Cash & Short-Term Investments | 311 M |
| Receivables | 4.39 B |
| Other Current Assets | 5.67 B |
| Non-Current Assets | 1.84 B |
| Long-Term Investments | 0 |
| PP&E | 777 M |
| Other Non-Current Assets | 1.06 B |
| Current Liabilities | 4.47 B |
| Accounts Payable | 3.35 B |
| Short-Term Debt | 601 M |
| Other Current Liabilities | 519 M |
| Non-Current Liabilities | 2.82 B |
| Long-Term Debt | 2.58 B |
| Other Non-Current Liabilities | 238 M |
EFFICIENCY
Earnings Waterfall
Avnet, Inc.
| Revenue | 23.8 B |
| Cost Of Revenue | 21 B |
| Gross Profit | 2.77 B |
| Operating Expenses | 1.87 B |
| Operating Income | 897 M |
| Other Expenses | 398 M |
| Net Income | 499 M |
RATIOS
11.64%
GROSS MARGIN
3.78%
OPERATING MARGIN
2.10%
NET MARGIN
10.12%
ROE
4.08%
ROA
8.98%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Avnet, Inc.
| Net Income | 499 M |
| Depreciation & Amortization | 141 M |
| Capital Expenditures | -226 M |
| Stock-Based Compensation | 33.5 M |
| Change in Working Capital | 11.2 M |
| Others | -242 M |
| Free Cash Flow | 464 M |
Wall Street Analysts Price Targets
Avnet, Inc.
AVT has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.60%
DIVIDEND YIELD
0.33 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Avnet, Inc.
Sold
0-3 MONTHS
200 K USD 1
3-6 MONTHS
3.1 M USD 5
6-9 MONTHS
1.11 M USD 2
9-12 MONTHS
717 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 months ago
Aug 29, 2024
|
Sell 200 K USD
|
LAWRENCE JAMES A
Director |
- 3642
|
54.83 USD |
|
3 months ago
Aug 15, 2024
|
Sell 67.1 K USD
|
McMullen Elizabeth
Senior VP - Operations |
- 1234
|
54.35 USD |
|
3 months ago
Aug 14, 2024
|
Sell 496 K USD
|
Chan Leng Jin
SVP, CIO |
- 9226
|
53.75 USD |
|
5 months ago
Jun 12, 2024
|
Sell 435 K USD
|
Arnold Ken E.
SVP, Chief People Officer |
- 8000
|
54.34 USD |
|
5 months ago
May 29, 2024
|
Sell 1.61 M USD
|
GALLAGHER PHILIP R
Chief Executive Officer |
- 30000
|
53.74 USD |
|
5 months ago
May 22, 2024
|
Sell 490 K USD
|
Bozotti Carlo
Director |
- 9000
|
54.4 USD |
|
6 months ago
May 10, 2024
|
Sell 1.01 M USD
|
GALLAGHER PHILIP R
Chief Executive Officer |
- 19532
|
51.63 USD |
|
8 months ago
Feb 22, 2024
|
Sell 102 K USD
|
Obregon-Jimenez Rebeca
SVP |
- 2210
|
46.04 USD |
|
11 months ago
Nov 24, 2023
|
Sell 387 K USD
|
LAWRENCE JAMES A
Director |
- 8190
|
47.3 USD |
|
11 months ago
Nov 21, 2023
|
Sell 329 K USD
|
LAWRENCE JAMES A
Director |
- 6910
|
47.68 USD |
|
1 year ago
May 15, 2023
|
Sell 1.35 M USD
|
GALLAGHER PHILIP R
Chief Executive Officer |
- 32740
|
41.35 USD |
|
1 year ago
May 11, 2023
|
Sell 3.04 M USD
|
LAWRENCE JAMES A
Director |
- 72851
|
41.69 USD |
|
2 years ago
Aug 18, 2022
|
Sell 1.09 M USD
|
Liguori Thomas
Chief Financial Officer |
- 24221
|
45.028 USD |
|
2 years ago
Aug 17, 2022
|
Sell 1.06 M USD
|
Liguori Thomas
Chief Financial Officer |
- 24221
|
43.918 USD |
|
2 years ago
Aug 16, 2022
|
Sell 902 K USD
|
Liguori Thomas
Chief Financial Officer |
- 20161
|
44.725 USD |
|
2 years ago
May 04, 2022
|
Sell 174 K USD
|
SCHUMANN WILLIAM H
director: |
- 3856
|
45.2 USD |
|
2 years ago
Feb 16, 2022
|
Sell 420 K USD
|
Chan Leng Jin
SVP, CIO |
- 10000
|
41.97 USD |
|
2 years ago
Feb 03, 2022
|
Sell 328 K USD
|
McMullen Elizabeth
Senior VP - Operations |
- 8000
|
41 USD |
|
2 years ago
Jan 18, 2022
|
Sell 908 K USD
|
Liguori Thomas
Chief Financial Officer |
- 21625
|
41.97 USD |
|
3 years ago
Sep 13, 2021
|
Sell 125 K USD
|
McMullen Elizabeth
Global VP - Operations |
- 3251
|
38.47 USD |
|
3 years ago
May 27, 2021
|
Sell 240 K USD
|
JACOBSON KENNETH A
Controller and PAO |
- 5360
|
44.7014 USD |
|
3 years ago
May 24, 2021
|
Sell 4.46 K USD
|
Arnold Ken E.
SVP, Chief People Officer |
- 100
|
44.63 USD |
|
3 years ago
May 24, 2021
|
Sell 152 K USD
|
Arnold Ken E.
SVP, Chief People Officer |
- 3400
|
44.68 USD |
|
3 years ago
May 07, 2021
|
Sell 443 K USD
|
Chan Leng Jin
CIO |
- 10000
|
44.2915 USD |
|
3 years ago
May 06, 2021
|
Sell 1.01 M USD
|
GALLAGHER PHILIP R
Chief Executive Officer |
- 23128
|
43.5722 USD |
|
3 years ago
May 04, 2021
|
Sell 902 K USD
|
GALLAGHER PHILIP R
CEO, President |
- 21152
|
42.6202 USD |
|
3 years ago
Feb 09, 2021
|
Sell 173 K USD
|
SCHUMANN WILLIAM H
Director |
- 4535
|
38.23 USD |
|
3 years ago
Dec 16, 2020
|
Bought 704 USD
|
Badhorn Dayna
Global VP, Strategic Planning |
+ 22
|
32.018 USD |
|
3 years ago
Dec 03, 2020
|
Bought 291 K USD
|
KHAYKIN OLEG
Director |
+ 9000
|
32.28 USD |
|
4 years ago
May 26, 2020
|
Sell 332 K USD
|
Miller MaryAnn G.
SVP, Chief Admin Officer |
- 11456
|
29 USD |
|
4 years ago
Mar 12, 2020
|
Bought 101 K USD
|
Liguori Thomas
Chief Financial Officer |
+ 4000
|
25.241 USD |
|
4 years ago
Dec 05, 2019
|
Sell 538 K USD
|
LAWRENCE JAMES A
Director |
- 13109
|
41.07 USD |
|
4 years ago
Dec 05, 2019
|
Sell 538 K USD
|
LAWRENCE JAMES A
Director |
- 13109
|
41.07 USD |
|
4 years ago
Dec 03, 2019
|
Sell 9.35 M USD
|
LAWRENCE JAMES A
Director |
- 237000
|
39.4352 USD |
|
4 years ago
Dec 04, 2019
|
Sell 1.09 M USD
|
LAWRENCE JAMES A
Director |
- 26891
|
40.5871 USD |
|
5 years ago
Sep 11, 2019
|
Sell 595 K USD
|
SCHUMANN WILLIAM H
Director |
- 13288
|
44.78 USD |
|
5 years ago
Sep 09, 2019
|
Sell 1.06 M USD
|
GALLAGHER PHILIP R
President |
- 24184
|
43.94 USD |
|
5 years ago
May 09, 2019
|
Sell 932 K USD
|
LAWRENCE JAMES A
Director |
- 20620
|
45.204 USD |
|
5 years ago
May 01, 2019
|
Sell 4.41 M USD
|
LAWRENCE JAMES A
Director |
- 91723
|
48.087 USD |
|
5 years ago
May 02, 2019
|
Sell 4.49 M USD
|
LAWRENCE JAMES A
Director |
- 95772
|
46.901 USD |
|
5 years ago
May 01, 2019
|
Sell 346 K USD
|
JACOBSON KENNETH A
Controller and PAO |
- 7205
|
48 USD |
|
5 years ago
May 02, 2019
|
Sell 27.8 K USD
|
JACOBSON KENNETH A
Controller and PAO |
- 591
|
46.975 USD |
|
5 years ago
Nov 29, 2018
|
Sell 1.04 M USD
|
GALLAGHER PHILIP R
President |
- 24068
|
43.18 USD |
|
6 years ago
Sep 14, 2018
|
Sell 659 K USD
|
Miller MaryAnn G.
Senior Vice President |
- 13724
|
47.99 USD |
|
6 years ago
Sep 14, 2018
|
Sell 52.8 K USD
|
Miller MaryAnn G.
Senior Vice President |
- 1100
|
48.02 USD |
|
6 years ago
Sep 14, 2018
|
Sell 9.6 K USD
|
Miller MaryAnn G.
Senior Vice President |
- 200
|
48.01 USD |
|
6 years ago
Feb 16, 2018
|
Sell 600 K USD
|
GALLAGHER PHILIP R
President |
- 14292
|
42 USD |
|
6 years ago
Feb 13, 2018
|
Sell 61.5 K USD
|
Summers Kevin V
Chief Information Officer |
- 1511
|
40.67 USD |
|
6 years ago
Dec 08, 2017
|
Bought 117 K USD
|
William Amelio J.
CEO |
+ 3000
|
39.16 USD |
|
7 years ago
Aug 17, 2017
|
Sell 393 K USD
|
BIGGINS J VERONICA
Director |
- 10600
|
37.1 USD |
|
7 years ago
Jun 02, 2017
|
Bought 128 K USD
|
LAWRENCE JAMES A
Director |
+ 3451
|
37.05 USD |
|
7 years ago
Jun 01, 2017
|
Bought 10.4 M USD
|
LAWRENCE JAMES A
Director |
+ 280000
|
37.17 USD |
|
7 years ago
May 31, 2017
|
Bought 4.57 M USD
|
LAWRENCE JAMES A
Director |
+ 125000
|
36.59 USD |
|
7 years ago
May 18, 2017
|
Bought 250 K USD
|
Moriarty Kevin M
CFO, Sr. VP |
+ 6933
|
36.08 USD |
|
7 years ago
Mar 01, 2017
|
Sell 235 K USD
|
Miller MaryAnn G.
Senior Vice President |
- 5000
|
47 USD |
|
7 years ago
Feb 07, 2017
|
Sell 140 K USD
|
ROBINSON RAY M
Director |
- 3004
|
46.45 USD |
7. News
International Markets and Avnet (AVT): A Deep Dive for Investors
Examine Avnet's (AVT) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
zacks.com
- 1 week ago
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT05, Alvotech's proposed biosimilar to Simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases. This is believed to be the first marketing authorization application filing announced globally for a biosimilar candidate to Simponi. The approvals process is anticipated to be completed in the fourth quarter of 2025. "This is a welcome milestone for us, our partners, patients and caregivers, as we take one step closer to being able to offer access to biosimilar Simponi®," said Joseph McClellan, Chief Scientific Officer of Alvotech. “We believe having the capability and know-how inhouse to utilize a host cell line and process also used to manufacture the reference biologic, has given us an important head start in developing a biosimilar candidate to Simponi®." “The EMA's acceptance of the application for AVT05 represents a significant step forward in expanding treatment options for patients with chronic inflammatory diseases across Europe,” said Nick Warwick, Chief Medical Officer of Advanz Pharma. “We are committed to improving patient access to high-quality biologic medicines.” Alvotech and Advanz Pharma first announced in February 2023 that the companies had entered into a commercialization agreement, for AVT23, a proposed biosimilar to Xolair® (omalizumab). In May this year, the partners announced an expansion of the strategic partnership, to include five additional biosimilar candidates being developed by Alvotech, AVT05, AVT16 a proposed biosimilar to Entyvio® (vedolizumab) and three additional early-stage biosimilar candidates which remain undisclosed. In April 2024 Alvotech announced positive top-line results from a confirmatory clinical study comparing efficacy, safety, and immunogenicity between AVT05 and Simponi® in patients with moderate to severe rheumatoid arthritis. In November 2023, Alvotech announced positive topline results from a pharmacokinetic study which assessed the pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® in healthy adult participants.
globenewswire.com
- 1 week ago
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
REYKJAVIK, Iceland and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT05, Alvotech's proposed biosimilar to Simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases. This is believed to be the first marketing authorization application filing announced globally for a biosimilar candidate to Simponi. The approvals process is anticipated to be completed in the fourth quarter of 2025.
globenewswire.com
- 1 week ago
Avnet Q1 Earnings Beat: Will Strong Sales View Lift the Stock?
AVT's Q1 results reflect continued weakness in the West and Farnell segments, which more than offsets the benefit from strong performance in Asia.
zacks.com
- 2 weeks ago
Avnet, Inc. (AVT) Q1 2025 Earnings Call Transcript
Avnet, Inc. (NASDAQ:AVT ) Q1 2025 Earnings Conference Call October 30, 2024 12:00 PM ET Company Participants Joe Burke - Vice President, Treasurer & Investor Relations Phil Gallagher - Chief Executive Officer Ken Jacobson - Chief Financial Officer Conference Call Participants Joe Quatrochi - Wells Fargo Ruplu Bhattacharya - Bank of America Matt Sheerin - Stifel William Stein - Truist Securities Operator Welcome to the Avnet First Quarter Fiscal Year 2025 Earnings Call. I would now like to turn the floor over to Joe Burke, Vice President of Treasury and Investor Relations for Avnet.
seekingalpha.com
- 2 weeks ago
Here's What Key Metrics Tell Us About Avnet (AVT) Q1 Earnings
While the top- and bottom-line numbers for Avnet (AVT) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
zacks.com
- 2 weeks ago
Avnet (AVT) Q1 Earnings and Revenues Surpass Estimates
Avnet (AVT) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $1.61 per share a year ago.
zacks.com
- 2 weeks ago
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT03, a proposed biosimilar candidate to Prolia® and Xgeva® (denosumab).
globenewswire.com
- 1 month ago
European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
REYKJAVIK, Iceland, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT03, a proposed biosimilar candidate to Prolia® and Xgeva® (denosumab).
globenewswire.com
- 1 month ago
Avnet to Support South East Water's Mass Digital Meter Deployment
MELBOURNE, Australia--(BUSINESS WIRE)---- $AVT #Avnet--Avnet has been awarded the contract to supply Huizhong's SCL61H-100 smart ultrasonic water meters to South East Water (SEW).
businesswire.com
- 2 months ago
12 Upcoming Dividend Increases
As fall approaches, twelve smaller financial institutions are set to increase dividends, averaging a 7.6% increase. My investment strategy focuses on companies with consistent dividend growth and outperforming benchmarks, using data from U.S. Dividend Champions and NASDAQ. SCHD outperformed most companies with a 197% total return over the past decade, with BR and CSWC showing notable performance.
seekingalpha.com
- 2 months ago
Daily Dividend Report: MMM, Halliburton, Avnet,Estee Lauder, CBOE
The 3M Board of Directors today declared a dividend on the company's common stock of $0.70 per share for the third quarter of 2024. The dividend is payable September 12, 2024, to shareholders of record at the close of business on August 26, 2024.
forbes.com
- 2 months ago
8. Profile Summary
Avnet, Inc. AVT
COUNTRY
US
INDUSTRY
Technology Distributors
MARKET CAP
$ 4.61 B
Dividend Yield
0.60%
Description
Avnet, Inc., a technology solutions company, markets, sells, and distributes electronic components. The company operates through two segments, Electronic Components and Farnell. The Electronic Components segment markets, sells, and distributes semiconductors; interconnect, passive, and electromechanical devices; and other integrated components from electronic component manufacturers. It also offers design chain support that provides engineers with technical design solutions; engineering and technical resources to support product design, bill of materials development, and technical education and training; and supply chain solutions that provide support and logistical services to original equipment manufacturers, electronic manufacturing service providers, and electronic component manufacturers. In addition, this segment provides integrated solutions, such as technical design, integration, and assembly of embedded products, and systems and solutions primarily for industrial applications, as well as for intelligent and innovative embedded display solutions comprising touch and passive displays. Further, it develops and manufactures standard board and industrial subsystems, and application-specific devices that enable it to produce systems tailored to specific customer requirements. This segment serves various markets, such as automotive, medical, defense, aerospace, telecommunications, industrial, and digital editing. The Farnell segment distributes kits, tools, and electronic and industrial automation components, as well as test and measurement products to engineers and entrepreneurs. It has operations in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Avnet, Inc. was founded in 1921 and is headquartered in Phoenix, Arizona.
Contact
2211 South 47th Street, Phoenix, AZ, 85034
https://www.avnet.com
IPO Date
May 3, 1973
Employees
15462
Officers
Heather Vana
Senior Director of Communications
Mr. David Jay Youngblood
Chief Digital Officer
Mr. Kenneth A. Jacobson
Chief Financial Officer
Mr. Philip R. Gallagher
Chief Executive Officer, President of Electronic Components, Member of Executive Board & Director
Mr. Leng-Jin Chan
Senior Vice President & Chief Information Officer
Mr. Joseph Burke
Vice President of Treasury & Investor Relations
Mr. Michael Ryan McCoy
Senior Vice President, General Counsel, Chief Legal Officer & Member of Executive Board
Mr. Ken E. Arnold
Senior Vice President, Chief People Officer & Member of Executive Board
Mr. Prince Yun
President of Avnet Asia Pacific
Ms. Elizabeth A. McMullen
Senior Vice President of Global Operations